Chairs:
TBC
AL AMYLOIDOSIS II
OP35The role of induction therapy before autologous stem cell transplantation in AL amyloidosis patients with bone marrow plasma cells less than 10%
Xianghua Huang, Jiangsu, China
OP36Ixazomib-dexamethasone versus physician’s choice in relapsed/refractory systemic al amyloidosis: Results from the phase 3 tourmaline-al1 trial
Giampaolo Merlini, Pavia, Italy
OP37Subcutaneous daratumumab + cyclophosphamide/bortezomib/dexamethasone in newly diagnosed al amyloidosis: Updated safety run-in results of andromeda
Raymond L. Comenzo, Boston, MA, USA
OP38Assessment of minimal residual disease using multiparametric flow cytometry in treated patients with al amyloidosis
Andrew Staron, Boston, MA, USA
OP39One-year evaluation of the incidence and distribution of amyloidosis diseases in Germany: National Clinical Amyloidosis Registry
Ute Hegenbart, Heidelberg, Germany
OP40Localised laryngeal amyloid – A series of 100 cases
Helen Lachmann, London, UK
Chair:
Giampaolo Merlini, Pavia, Italy
Panelists:
Stefan Schönland, Heidelberg, Germany
Vaishali Sanchorawala, Boston, MA, USA
Arnaud Jaccard, Limoges, France
Bouke Hazenberg, Groningen, The Netherlands
Bruno Paiva, Pamplona, Spain
Rámon Lecumberri, Pamplona, Spain
Topics:
• When to suspect AL amyloidosis during MGUS follow-up?
• New response criteria needed?
• Is there a role for MRD assessment?
• Are we curing AL amyloidosis in 2020?
• Amyloid deposition in organ transplant recipients?
Chair:
Matthias Schmidt, Ulm, Germany
Panelists:
Ole Suhr, Umeå, Sweden
Violaine Plante-Bordeneuve, Créteil, France
Esther González-López, Madrid, Spain
Joel Buxbaum, La Jolla, CA, USA
Juan Buades, Palma de Mallorca, Spain
Topics:
• What is the real prevalence of wild type ATTR amyloidosis?
• What are the critical endpoints in ATTR polyneuropathy?
• Best treatment approach at lack of response to patisiran or inotersen?
• Is it time for combination therapy trials?
• What is the best approach to ATTR mutant carriers?
Clinical Trials in Progress in Systemic Amyloidosis